NCT00287872 · OUTCOME

Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma · Source last updated 2018-03-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).

The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide. bortezomib thalidomide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bortezomib and Thalidomide	27

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Bortezomib and Thalidomide	19	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Neuropathy was monitored using Total Neuropathy Score reduced (TNSr).

groups

param Type

NUMBER

reporting Status

POSTED

time Frame

1-6 months

title

Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice